AbbVie enters obesity treatment via Gubra licensing agreement
In This Article:
AbbVie (ABBV) is entering into the weight-loss space after partnering with Gubra through a licensing agreement. Market Domination's Julie Hyman and Josh Lipton break down this possible alternative to GLP-1 drugs.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
This post was written by Luke Carberry Mogan.
Related Videos
Terms and Privacy Policy